199 related articles for article (PubMed ID: 20152241)
1. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).
Sarno G; Garg S; Onuma Y; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; Eerdmans P; Garcia-Garcia HM; van Es GA; Goedhart D; de Vries T; Jüni P; Meier B; Windecker S; Serruys P
Am J Cardiol; 2010 Feb; 105(4):475-9. PubMed ID: 20152241
[TBL] [Abstract][Full Text] [Related]
2. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
3. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.
Sarno G; Räber L; Onuma Y; Garg S; Brugaletta S; van Domburg RT; Pilgrim T; Pfäffli N; Wenaweser P; Windecker S; Serruys P
Am J Cardiol; 2011 Jul; 108(2):195-201. PubMed ID: 21529741
[TBL] [Abstract][Full Text] [Related]
4. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
[TBL] [Abstract][Full Text] [Related]
5. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.
Räber L; Kelbæk H; Ostojic M; Baumbach A; Heg D; Tüller D; von Birgelen C; Roffi M; Moschovitis A; Khattab AA; Wenaweser P; Bonvini R; Pedrazzini G; Kornowski R; Weber K; Trelle S; Lüscher TF; Taniwaki M; Matter CM; Meier B; Jüni P; Windecker S;
JAMA; 2012 Aug; 308(8):777-87. PubMed ID: 22910755
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
[TBL] [Abstract][Full Text] [Related]
7. Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents.
Novack V; Nguyen MC; Rooney M; Chacko R; Novack L; Pencina M; Apruzzese P; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
Am J Cardiol; 2010 Sep; 106(6):774-9. PubMed ID: 20816116
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
9. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
[TBL] [Abstract][Full Text] [Related]
11. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial.
Räber L; Kelbæk H; Taniwaki M; Ostojic M; Heg D; Baumbach A; von Birgelen C; Roffi M; Tüller D; Engstrøm T; Moschovitis A; Pedrazzini G; Wenaweser P; Kornowski R; Weber K; Lüscher TF; Matter CM; Meier B; Jüni P; Windecker S;
Circ Cardiovasc Interv; 2014 Jun; 7(3):355-64. PubMed ID: 24847017
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Jensen LO; Thayssen P; Hansen HS; Christiansen EH; Tilsted HH; Krusell LR; Villadsen AB; Junker A; Hansen KN; Kaltoft A; Maeng M; Pedersen KE; Kristensen SD; Bøtker HE; Ravkilde J; Sanchez R; Aarøe J; Madsen M; Sørensen HT; Thuesen L; Lassen JF;
Circulation; 2012 Mar; 125(10):1246-55. PubMed ID: 22308301
[TBL] [Abstract][Full Text] [Related]
13. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
14. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
15. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
Windecker S; Serruys PW; Wandel S; Buszman P; Trznadel S; Linke A; Lenk K; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Davies S; van Geuns RJ; Eerdmans P; van Es GA; Meier B; Jüni P
Lancet; 2008 Sep; 372(9644):1163-73. PubMed ID: 18765162
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
Nikolsky E; Kosinski E; Mishkel GJ; Kimmelstiel C; McGarry TF; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW
Am J Cardiol; 2005 Mar; 95(6):709-15. PubMed ID: 15757595
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
